Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma

Abstract

Summary To evaluate the clinical significance of serum levels of hepatocyte growth factor (HGF) in colorectal cancer patients, we measured the venous and portal concentrations of HGF in 60 patients. The tissue concentrations in the tumour and adjacent normal mucosa were also determined. The serum HGF concentration for the peripheral venous blood of the patients was significantly higher than that in normal controls. The content of HGF in cancer tissue was also significantly higher than that in normal mucosa, and it was correlated with the serum HGF concentration for the peripheral venous blood. The serum concentration of HGF reflected pathological features, including tumour size and lymph node or liver metastasis, and it showed an association with various preoperative nutritional parameters and the preoperative haemoglobin level. The serum HGF concentration was also correlated with the serum concentrations of immunosuppressive acidic protein and interleukin-6, indices of the host's immunological condition. Serum HGF seems to be a useful index of the disease status of patients with colorectal carcinoma.Keywords: hepatocyte growth factor; nutritional status; immunological status; colorectal cancer Hepatocyte growth factor (HGF) is a multifunctional cytokine that is the most potent known stimulator of hepatocyte growth and DNA synthesis Kaneko et al, 1992). HGF has also been recognized as a tumour-disseminating factor (Weidner et al, 1991;Mayer et al, 1993;Tannapfel et al, 1994). In several experimental studies, evidence has been acquired of a relation of HGF to the progression of tumour cells . Among the particularly important biological activities of HGF in tumour cells is its capacity to increase epithelial cell proliferation and motility (Gherardi et al, 1990). In clinical studies, a relationship between the concentration of HGF in serum or cancer tissue and the progression of disease has been noted in patients with gastric cancer (Taniguchi et al, 1997), oesophageal cancer (Takada et al, 1995) and breast cancer (Yamashita et al, 1994;Taniguchi et al, 1995). However, there are no reports regarding the clinical relevance of HGF in patients with colorectal carcinoma.Malnutrition or immunosuppression are involved in the development of life-threatening complications in patients with malignancies (Braga et al, 1988;Nishi et al, 1988;Dannhauser et al, 1995;Triantafillidis et al, 1995;Windsor et al, 1995;Goransson et al, 1996). Patients with advanced cancer and cachexia typically demonstrate modestly increased rates of energy expenditure with concomitant diminished food intake. These metabolic changes may be due to mediators released by the tumour or by the host (Keller, 1993). Recently, the role of cytokines in these metabolic changes was emphasized (Gambardella et al, 1997). In addition, the relationship between cytokines and an immunosuppressive substance has also been highlighted (Tanaka et al, 1993 The objective of this study was to evaluate the relationship between serum HGF concentration and clinicopathological ...

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

“…Previous studies have investigated MET in CRC with semiquantitative techniques such as immunoblotting or IHC (Di Renzo et al, 1995;Hiscox et al, 1997;Fujita and Sugano, 1997;Fukuura et al, 1998). Our study represents the first report in CRC assessing MET at the genomic level using FISH.…”

A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors

“…The expression of HGF/SF and c-Met and aberrant signaling via the HGF/SF:c-Met axis have been implicated in the development and progression of human cancers (5,7,(37)(38)(39)(40)(41). For example, among patients with solid tumors, HGF/SF (42) and c-Met (43-47) expression has been associated with poor prognosis, tumor invasiveness, and/or migration.…”

Metastatic squamous cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor

“…Yu et al recently showed that a nonautocrine interaction between HGF transgenic hosts and c-Met expressing melanoma cells significantly promotes tumor metastasis in vivo (Yu and Merlino, 2002). Clinically, elevated serum HGF levels have been found in patients with cancers from bladder, breast, colon, gastric, liver, lung and head and neck (Takigawa et al, 1997;Taniguchi et al, 1997;Fukuura et al, 1998;Toi et al, 1998;Junbo et al, 1999;Gohji et al, 2000;Naughton et al, 2001;Uchida et al, 2001, Dong, 2001b. Significantly, this elevated serum HGF is associated with poor prognosis.…”